Goldman Sachs Group Inc Gamida Cell Ltd. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	BUY	$0.73 - $2.37 $76,436 - $248,155	104,707 Added 283.94%	141,583 $273,000
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $103,355 - $335,551	141,583 New	141,583 $273,000
Q4 2022 May 14, 2024	SELL	$1.15 - $2.1 $50,856 - $92,868	-44,223 Reduced 54.53%	36,876 $47,000
Q4 2022 Feb 13, 2023	SELL	$1.15 - $2.1 $50,856 - $92,868	-44,223 Reduced 54.53%	36,876 $47,000
Q3 2022 May 14, 2024	BUY	$1.53 - $3.39 $32,125 - $71,179	20,997 Added 34.94%	81,099 $129,000
Q3 2022 Nov 10, 2022	BUY	$1.53 - $3.39 $32,125 - $71,179	20,997 Added 34.94%	81,099 $0
Q2 2022 May 14, 2024	BUY	$1.73 - $4.29 $103,976 - $257,837	60,102 New	60,102 $106,000
Q2 2022 Aug 15, 2022	BUY	$1.73 - $4.29 $66,705 - $165,413	38,558 Added 178.97%	60,102 $106,000
Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $37,602 - $75,712	-16,938 Reduced 44.02%	21,544 $89,000
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $89,194 - $180,821	-40,543 Reduced 51.3%	38,482 $98,000
Q3 2021 Nov 10, 2021	BUY	$3.85 - $6.44 $304,246 - $508,921	79,025 New	79,025 $310,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.